Cencora, Inc. (NYSE:COR) Position Boosted by CWA Asset Management Group LLC

CWA Asset Management Group LLC increased its holdings in Cencora, Inc. (NYSE:COR) by 9.8% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 1,715 shares of the company’s stock after purchasing an additional 153 shares during the quarter. CWA Asset Management Group LLC’s holdings in Cencora were worth $477,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also added to or reduced their stakes in COR. Hoey Investments Inc. bought a new position in Cencora in the 1st quarter worth approximately $28,000. Banque Transatlantique SA bought a new position in Cencora in the 4th quarter worth approximately $29,000. SBI Securities Co. Ltd. bought a new position in Cencora in the 4th quarter worth approximately $30,000. Vermillion Wealth Management Inc. bought a new position in Cencora in the 4th quarter worth approximately $38,000. Finally, OFI Invest Asset Management bought a new position in Cencora in the 4th quarter worth approximately $41,000. 97.52% of the stock is owned by institutional investors.

Insider Buying and Selling at Cencora

In related news, CEO Robert P. Mauch sold 4,969 shares of Cencora stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the sale, the chief executive officer now directly owns 47,582 shares of the company’s stock, valued at $13,766,900.06. This trade represents a 9.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Steven H. Collis sold 14,578 shares of the firm’s stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $269.51, for a total transaction of $3,928,916.78. Following the transaction, the chairman now owns 317,913 shares of the company’s stock, valued at approximately $85,680,732.63. This represents a 4.38% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 38,253 shares of company stock worth $10,582,297 over the last three months. Corporate insiders own 10.80% of the company’s stock.

Cencora Stock Performance

COR opened at $293.66 on Friday. The business has a fifty day simple moving average of $288.98 and a 200-day simple moving average of $263.19. The firm has a market cap of $56.92 billion, a PE ratio of 34.07, a P/E/G ratio of 1.47 and a beta of 0.58. Cencora, Inc. has a fifty-two week low of $218.65 and a fifty-two week high of $309.35. The company has a quick ratio of 0.52, a current ratio of 0.87 and a debt-to-equity ratio of 6.01.

Cencora (NYSE:COR) last released its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.07 by $0.35. The company had revenue of $75.50 billion during the quarter, compared to analyst estimates of $75.41 billion. Cencora had a return on equity of 344.71% and a net margin of 0.55%. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.80 earnings per share. As a group, equities analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, June 2nd. Shareholders of record on Friday, May 16th were issued a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, May 16th. This represents a $2.20 annualized dividend and a yield of 0.75%. Cencora’s dividend payout ratio (DPR) is currently 25.52%.

Analysts Set New Price Targets

COR has been the subject of a number of recent analyst reports. Robert W. Baird increased their price objective on Cencora from $314.00 to $350.00 and gave the stock an “outperform” rating in a report on Thursday, May 8th. Bank of America increased their price target on Cencora from $270.00 to $285.00 and gave the company a “neutral” rating in a research note on Friday, April 11th. Citigroup increased their price target on Cencora from $330.00 to $355.00 and gave the company a “buy” rating in a research note on Thursday, May 8th. Morgan Stanley set a $288.00 price target on Cencora in a research note on Tuesday, April 15th. Finally, UBS Group raised their price objective on Cencora from $298.00 to $335.00 and gave the stock a “buy” rating in a research note on Tuesday, April 29th. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $306.91.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.